- Home
- SLP vs LCTX Comparison
SLP vs LCTX Comparison
Compare SLP & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- LCTX
- Stock Information
- Founded
- SLP 1996
- LCTX 1990
- Country
- SLP United States
- LCTX United States
- Employees
- SLP N/A
- LCTX N/A
- Industry
- SLP EDP Services
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLP Technology
- LCTX Health Care
- Exchange
- SLP Nasdaq
- LCTX Nasdaq
- Market Cap
- SLP 286.6M
- LCTX 274.0M
- IPO Year
- SLP 1997
- LCTX N/A
- Fundamental
- Price
- SLP $14.57
- LCTX $1.21
- Analyst Decision
- SLP Buy
- LCTX Strong Buy
- Analyst Count
- SLP 7
- LCTX 5
- Target Price
- SLP $29.50
- LCTX $4.20
- AVG Volume (30 Days)
- SLP 429.3K
- LCTX 1.6M
- Earning Date
- SLP 10-22-2025
- LCTX 08-12-2025
- Dividend Yield
- SLP N/A
- LCTX N/A
- EPS Growth
- SLP N/A
- LCTX N/A
- EPS
- SLP N/A
- LCTX N/A
- Revenue
- SLP $80,383,000.00
- LCTX $10,914,000.00
- Revenue This Year
- SLP $12.75
- LCTX N/A
- Revenue Next Year
- SLP $3.06
- LCTX $244.95
- P/E Ratio
- SLP N/A
- LCTX N/A
- Revenue Growth
- SLP 20.01
- LCTX 76.43
- 52 Week Low
- SLP $12.39
- LCTX $0.37
- 52 Week High
- SLP $37.72
- LCTX $1.31
- Technical
- Relative Strength Index (RSI)
- SLP 50.24
- LCTX 62.25
- Support Level
- SLP $13.70
- LCTX $1.15
- Resistance Level
- SLP $14.88
- LCTX $1.29
- Average True Range (ATR)
- SLP 0.58
- LCTX 0.08
- MACD
- SLP 0.29
- LCTX 0.02
- Stochastic Oscillator
- SLP 86.28
- LCTX 72.22
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.